Before matching | After matching | |||||
---|---|---|---|---|---|---|
Classical group | ICG circular group | P value | Classical group | ICG circular group | P value | |
(n = 82) | (n = 39) | (n = 33) | (n = 33) | |||
Age (years) | 0.892 | 0.872 | ||||
Median (quartiles) | 66 (61–72) | 66 (61–71) | 65 (61–73) | 67 (63–73) | ||
Sex | 0.914 | 0.282 | ||||
Male | 70 (85%) | 33 (85%) | 30 (90%) | 27 (82%) | ||
Female | 12 (15%) | 6 (15%) | 3 (9%) | 6 (18%) | ||
Body mass index (kg/m2) | 21.2 ± 3.1 | 22.2 ± 3.3 | 0.083 | 21.8 ± 3.1 | 21.9 ± 3.3 | 0.677 |
Serum albumin level (g/dL) | 4.2 ± 0.4 | 4.1 ± 0.4 | 0.494 | 4.1 ± 0.4 | 4.1 ± 0.4 | 0.985 |
Brinkman index | 0.733 | 0.278 | ||||
Median (quartiles) | 800 (445–1000) | 860 (435–1000) | 820 (600–1140) | 840 (405–1000) | ||
ECOG performance status | 0.586 | 0.601 | ||||
0 | 68 (83%) | 34 (87%) | 27 (82%) | 28 (85%) | ||
1 | 12 (15%) | 5 (13%) | 5 (15%) | 5 (15%) | ||
2 | 2 (2%) | 0 (0%) | 1 (3%) | 0 (0%) | ||
Comorbidity | ||||||
Diabetes | 15 (18%) | 4 (10%) | 0.256 | 10 (30%) | 4 (12%) | 0.071 |
Cardiovascular disease | 10 (12%) | 6 (15%) | 0.628 | 2 (6%) | 5 (15%) | 0.230 |
Obstructive ventilation failure | 27 (33%) | 13 (33%) | 0.965 | 10 (30%) | 11 (33%) | 0.792 |
ASA-PS score | 0.021 | 0.115 | ||||
1 | 11 (13%) | 1 (3%) | 3 (9%) | 1 (3%) | ||
2 | 63 (77%) | 28 (72%) | 27 (82%) | 23 (70%) | ||
3 | 8 (10%) | 10 (26%) | 3 (9%) | 9 (27%) | ||
Histological type | 0.009 | 1.000 | ||||
Squamous cell carcinoma | 78 (95%) | 30 (77%) | 30 (91%) | 30 (91%) | ||
Adenocarcinoma | 2 (2%) | 6 (15%) | 2 (6%) | 2 (6%) | ||
Others | 2 (2%) | 3 (8%) | 1 (3%) | 1 (3%) | ||
Tumor location | 0.229 | 0.642 | ||||
Upper thoracic | 11 (13%) | 6 (15%) | 5 (15%) | 6 (18%) | ||
Middle thoracic | 43 (52%) | 16 (41%) | 15 (46%) | 16 (49%) | ||
Lower thoracic | 24 (29%) | 11 (28%) | 11 (33%) | 7 (21%) | ||
Abdominal | 4 (5%) | 6 (15%) | 2 (6%) | 4 (12%) | ||
cT | 0.405 | 0.667 | ||||
1 | 36 (44%) | 16 (41%) | 16 (49%) | 14 (42%) | ||
2 | 14 (17%) | 11 (28%) | 5 (15%) | 9 (27%) | ||
3 | 31 (38%) | 11 (28%) | 11 (33%) | 9 (27%) | ||
4a | 1 (1%) | 1 (3%) | 1 (3%) | 1 (3%) | ||
cN | 0.224 | 0.420 | ||||
0 | 44 (54%) | 28 (72%) | 19 (58%) | 24 (73%) | ||
1 | 17 (21%) | 5 (13%) | 7 (21%) | 4 (12%) | ||
2 | 20 (24%) | 5 (13%) | 7 (21%) | 5 (15%) | ||
3 | 1 (1%) | 1 (3%) | 0 (0%) | 0 (0%) | ||
cStage | 0.296 | 0.393 | ||||
1 | 32 (39%) | 14 (36%) | 16 (49%) | 13 (39%) | ||
2 | 19 (23%) | 14 (36%) | 5 (15%) | 10 (30%) | ||
3 | 31 (38%) | 11 (28%) | 12 (36%) | 10 (30%) | ||
Neoadjuvant chemotherapy | 0.974 | 1.000 | ||||
Absent | 36 (44%) | 17 (44%) | 16 (49%) | 16 (49%) | ||
Present | 46 (56%) | 22 (56%) | 17 (52%) | 17 (52%) |